Skip to Search
Skip to Main Content
Skip to Footer
Databases A-Z
Library Registration
Request Literature Search
Login
User Login
Username
*
Password
*
Administration Login
×
Databases A-Z
Library Registration
Request Literature Search
Login
Gateshead Health
NHS Foundation Trust
Menu
Site Search
Search Options
Library Search
Multiple Sources
Catalogue
NICE
BNF
BNFc
All Library Online Resources
eBooks
Journals
BMJ Best Practice
NEJM
Royal Marsden
UpToDate
MHRA
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...
Paclitaxel coated devices (PCD) used in the treatment of peripheral arterial disease: update to previous MHRA guidance on use. Where indicated, PCD can be considered as a treatment option for both critical limb ischaemia (CLI) and intermittent...
Guidance: Advice for consumers
Class 4 Medicines Defect Information: Exeltis UK Limited, Gepretix 100mg Capsules, EL (24)A/04
Field Safety Notices (FSNs) from 22 to 26 January 2024
Press release: MHRA announces two new UK Approved Bodies to certify medical devices
News story: New valproate safety measures apply from 31 January
Press release: Omjjara licensed for anaemic myelofibrosis patients to treat the symptoms of their disease
Guidance: Medical devices: UK approved bodies
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×